Atebrioz gains US FDA approval for fibrodysplasia ossificans progressiva as the first oral therapy for the ultra-rare disease.
Atebrioz gains US FDA approval for fibrodysplasia ossificans progressiva as the first oral therapy for the ultra-rare disease.